Pharsight

Drugs that contain Rucaparib Camsylate

1. Rubraca patents expiration

RUBRACA's oppositions filed in EPO
RUBRACA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6495541 CLOVIS ONCOLOGY INC Tricyclic inhibitors of poly(ADP-ribose) polymerases
Nov, 2023

(3 months ago)

US8754072 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(6 years from now)

US9045487 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7531530 CLOVIS ONCOLOGY INC Therapeutic compounds
Jul, 2024

(4 months from now)

US7351701 CLOVIS ONCOLOGY INC Therapeutic compounds
Jul, 2024

(4 months from now)

US8071579 CLOVIS ONCOLOGY INC DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US8143241 CLOVIS ONCOLOGY INC DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

US9861638 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(6 years from now)

US10278974 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(6 years from now)

US8859562 CLOVIS ONCOLOGY INC Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

US9987285 CLOVIS ONCOLOGY INC High dosage strength tablets of rucaparib
Aug, 2035

(11 years from now)

US10130636 CLOVIS ONCOLOGY INC High dosage strength tablets of rucaparib
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 6, 2025

Market Authorisation Date: 19 December, 2016

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by admin...

Dosage: TABLET;ORAL

More Information on Dosage

RUBRACA family patents

Family Patents